Hatteras Venture Partners is a venture capital firm founded in 2000 and based in Durham, North Carolina. The firm specializes in seed and early-stage investments in the life sciences sector, focusing on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related human medicine opportunities. Hatteras is particularly active in the Southeastern United States, aiming to build transformational companies that improve health through innovative therapies and disruptive technologies.

The firm has approximately $450 million under management across five funds and has invested in companies such as G1 Therapeutics, Clearside Biomedical, GrayBug Vision, Viamet Pharmaceuticals, Lysosomal Therapeutics, Orig3n, Clinipace, and GeneCentric.